

Ida Annunziata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3168918/publications.pdf>

Version: 2024-02-01

21
papers

873
citations

687363

13
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

1109
citing authors

#	ARTICLE	IF	CITATIONS
1	Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 191-203.	4.1	9
2	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. <i>FASEB BioAdvances</i> , 2021, 3, 192-197.	2.4	2
3	Lysosomes and Cancer Progression: A Malignant Liaison. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 642494.	3.7	38
4	GM1 Gangliosidosis – A Mini-Review. <i>Frontiers in Genetics</i> , 2021, 12, 734878.	2.3	38
5	AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 644-658.	4.1	8
6	Transcription factor competition regulates lysosomal biogenesis and autophagy. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1685840.	0.7	4
7	Isolation and Characterization of Exosomes from Skeletal Muscle Fibroblasts. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	2
8	Generation of human induced pluripotent stem cells (hiPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations. <i>Stem Cell Research</i> , 2020, 46, 101836.	0.7	4
9	Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I. <i>Journal of Clinical Medicine</i> , 2020, 9, 695.	2.4	13
10	Isolation, Purification and Characterization of Exosomes from Fibroblast Cultures of Skeletal Muscle. <i>Bio-protocol</i> , 2020, 10, e3576.	0.4	4
11	MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. <i>Nature Communications</i> , 2019, 10, 3623.	12.8	71
12	Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis. <i>Science Advances</i> , 2019, 5, eaav3270.	10.3	42
13	Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. <i>Cell Death and Disease</i> , 2018, 9, 328.	6.3	84
14	Galactosialidosis: historic aspects and overview of investigated and emerging treatment options. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 131-141.	0.8	27
15	Regulated lysosomal exocytosis mediates cancer progression. <i>Science Advances</i> , 2015, 1, e1500603.	10.3	108
16	Pathogenesis, emerging therapeutic targets and treatment in sialidosis. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 491-504.	0.8	56
17	Loss of Cellular Sialidases Does Not Affect the Sialylation Status of the Prion Protein but Increases the Amounts of Its Proteolytic Fragment C1. <i>PLoS ONE</i> , 2015, 10, e0143218.	2.5	17
18	Lysosomal multienzyme complex: pros and cons of working together. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 2017-2032.	5.4	209

#	ARTICLE	IF	CITATIONS
19	Mitochondria-associated ER Membranes (MAMs) and Glycosphingolipid Enriched Microdomains (GEMs): Isolation from Mouse Brain. <i>Journal of Visualized Experiments</i> , 2013, , e50215.	0.3	14
20	Interorganellar Membrane Microdomains: Dynamic Platforms in the Control of Calcium Signaling and Apoptosis. <i>Cells</i> , 2013, 2, 574-590.	4.1	14
21	Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid- β^2 secretion via deregulated lysosomal exocytosis. <i>Nature Communications</i> , 2013, 4, 2734.	12.8	109